Addex Gives Vague Update on Q1 Data Readout
Insights - This morning, Addex (ADXN) announced that Janssen has completed the enrolment of Part 1 of their Phase 2 clinical study of ADX71149 in epilepsy. Data … Continue Reading
Premium: Read NowInsights
2023 Names & Themes To Watch
Insights - Below are a few names to watch, each divided into a different segment. Value: Atyr Pharma (LIFE)Atyr Pharma is currently enrolling for a pivotal Phase … Continue Reading
Premium: Read Now
NK Sentiment and Impact on Affimed
Insights - Biotech (XBI) had a rocky 2022, seeing a near vertical drop in 1H 2022 and settling in around the low-$80 range in the second half … Continue Reading
Premium: Read Now
Notes from KOL on AFM13+NK ASH2022 Data
Insights - Yesterday, Slingshot Insights had a call with a lymphoma KOL on Affimed’s (AFMD) AFM13+NK data that was presented at ASH earlier in December. From an … Continue Reading
Premium: Read Now
Affimed Scraps Mono AFM13 To Focus on Combinations
Insights - Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination w/ NK. The monotherapy data … Continue Reading
Premium: Read Now
Astria Runs Ahead of Phase 1 Readout
Insights - Astria (ATXS) expects preliminary results from Phase 1a trial of STAR-0215 by year end 2022. The trial aims to establish the prolonged half-life and demonstrate inhibition … Continue Reading
Premium: Read Now
Jounce Announces Yet Another Delay
Insights - Jounce Announces Yet Another DelayJounce will be reporting their Phase 2 proof of concept data for their LILRB2/ILT4 target in the 1H 2023. This timeline … Continue Reading
Premium: Read Now